Table S1: Strains and plasmids used in this study

Strain	Lab #	Species	Parent	Relevant Characteristics or Genotype	Source
Fungal Strains					
U04 (A04)	DH2949	*C. lusitaniae*		Clinical isolate, FLZ-resistant, *MRR1*^{Y813C}	(1, 2)
U04 *mrr1*Δ	DH3306	*C. lusitaniae*	U04	*mrr1*Δ::*NAT1*	(2)
U04 *mrr1*Δ + *MRR1*^{Y813C} (Y8)	DH3613	*C. lusitaniae*	U04 *mrr1*Δ	*MRR1*^{Y813C}-*HygB*	This study
U04 *mrr1*Δ + *MRR1*$^{L1191H+Q1197*}$ (L1Q1*)	DH3628	*C. lusitaniae*	U04 *mrr1*Δ	*MRR1*$^{L1191H+Q1197*}$-*HygB*	This study
U05	DH3087	*C. lusitaniae*		Clinical isolate, FLZ-susceptible, *MRR1*$^{L1191H+Q1197*}$	(2)
L14	DH3088	*C. lusitaniae*		Clinical isolate, FLZ-susceptible, *MRR1*$^{L1191H+Q1197*}$	(2)
L17	DH3101	*C. lusitaniae*		Clinical isolate, FLZ-resistant, *MRR1*^{H467L}	(2)
L17 *mrr1*Δ	DH3110	*C. lusitaniae*	L17	*mrr1*Δ::*NAT1*	(2)
L17 *cap1*Δ	DH3720	*C. lusitaniae*	L17	*cap1*Δ::*NAT1*	This study
L17 *mgd1*Δ	DH3724	*C. lusitaniae*	L17	*mgd1*Δ::*NAT1*	This study
L17 *mgd2*Δ	DH3726	*C. lusitaniae*	L17	*mgd2*Δ::*NAT1*	This study
S18	DH3102	*C. lusitaniae*		Clinical isolate, FLZ-resistant, *MRR1*^{H467L}	(2)
S18 *mrr1*Δ	DH3718	*C. lusitaniae*	S18	*mrr1*Δ::*NAT1*	This study
S18 *cap1*Δ	DH3719	*C. lusitaniae*	S18	*cap1*Δ::*HygB*	This study
S18 *mrr1*Δ/*cap1*Δ	DH3721	*C. lusitaniae*	S18 *cap1*Δ	*cap1*Δ::*HygB*/*mrr1*Δ::*NAT1*	This study
S18 *mdr1*Δ	DH3722	*C. lusitaniae*	S18	*mdr1*Δ::*HygB*	This study
S18 *mgd1*Δ	DH3723	*C. lusitaniae*	S18	*mgd1*Δ::*NAT1*	This study
S18 *mgd2*Δ	DH3725	*C. lusitaniae*	S18	*mgd2*Δ::*HygB*	This study
S18 *mgd1*Δ/*mgd2*Δ	DH3727	*C. lusitaniae*	S18 *mgd1*Δ	*mgd1*Δ::*NAT1*/*mgd2*Δ::*HygB*	This study
S18 *glo1*Δ	DH3728	*C. lusitaniae*	S18	*glo1*Δ::*NAT1*	This study
SC5314	DH35	*C. albicans*		Wild-type *C. albicans* lab strain	(3)
F2	DH3550	*C. albicans*		Clinical isolate, FLZ-susceptible	(4)
F5	DH3551	*C. albicans*		Clinical isolate, FLZ-resistant	(4)
Wü284	DH2178	*C. dubliniensis*		Clinical isolate	(5)
CM1	DH3575	*C. dubliniensis*		Clinical isolate, FLZ-susceptible	(6)
CM2	DH3576	*C. dubliniensis*		Clinical isolate, FLZ-resistant	(6)
RC-601	DH1989	*C. parapsilosis*		Clinical isolate	(7)
JB6	DH3595	*C. parapsilosis*		CLIB24 *mrr1*Δ + *MRR1*^{Q1064P}	(8)
JB12	DH3596	*C. parapsilosis*		CLIB24 *mrr1*Δ + *MRR1*^{K873N}	(8)
ATCC 6260 (RC-401)	DH1984	*C. guilliermondii*		Clinical isolate	(7)

RC-201	DH1986	*C. glabrata*	Clinical isolate	(7)
ATCC 2001	DH2788	*C. glabrata*	Clinical isolate	(9)
CAU-01	DH2768	*C. auris*	Clinical isolate	(10)
CAU-02	DH2769	*C. auris*	Clinical isolate	(10)
CAU-03	DH2770	*C. auris*	Clinical isolate	(10)
CAU-04	DH2771	*C. auris*	Clinical isolate	(10)
CAU-05	DH2772	*C. auris*	Clinical isolate	(10)
Y533	DH1981	*C. lusitaniae*	Clinical isolate	(11)
RC-301	DH1987	*C. lusitaniae*	Clinical isolate	(7)
UCDFST 80-11	DH3119	*C. lusitaniae*	Environmental isolate	Phaff Yeast Culture Collection, University of California, Davis*
UCDFST 80-11	DH3120	*C. lusitaniae*	Environmental isolate	Phaff Yeast Culture Collection, University of California, Davis*
Plasmids in *E. coli* (DH5α)				
pMQ30$^{MRR1\text{-}L1191H+Q1197*}$	DH3829	*E. coli*	*MRR1*$^{L1191H+Q1197*}$*-HygB* complementation, Gent^{R}	This study
pMQ30$^{MRR1\text{-}Y813C}$	DH3831	*E. coli*	*MRR1*^{Y813C}*-HygB* complementation, Gent^{R}	This study
pNAT	DH2664	*E. coli*	TEF1p-*NAT1*, Amp/Carb^{R}	(12)
pYM70	DH3352	*E. coli*	TEF2p-*HygB*, Amp/Carb^{R}	(13)
pGEM-*URA3*	DH3316	*E. coli*	pGEM-T (Promega) containing *CaURA3,* Gent^{R}	(14)
pMQ30	DH2620	*E. coli*	Plasmid that replicates in *S. cerevisiae* and *E. coli*, using uracil or gentamycin selection, respectively	(15)

[a]UCDFST, Phaff Yeast Culture Collection, Food Science and Technology, University of California Davis; ATCC, American Type Culture Collection.

References

1. Grahl N, Demers EG, Crocker AW, Hogan DA. Use of RNA-protein complexes for genome editing in non-albicans *Candida* species. mSphere. 2017;2(3).
2. Demers EG, Biermann AR, Masonjones S, Crocker AW, Ashare A, Stajich JE, et al. Evolution of drug resistance in an antifungal-naive chronic *Candida lusitaniae* infection. Proc Natl Acad Sci U S A. 2018;115(47):12040-5.
3. Gillum AM, Tsay EYH, Kirsch DR. Isolation of the *Candida-Albicans* gene for orotidine-5'-phosphate decarboxylase by complementation of *S. Cerevisiae* Ura3 and *Escherichia Coli* Pyrf mutations. Mol Gen Genet. 1984;198(1):179-82.

4. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical *Candida albicans* strains. Antimicrob Agents Chemother. 1998;42(12):3065-72.
5. Morschhauser J, Ruhnke M, Michel S, Hacker J. Identification of CARE-2-negative *Candida* albicans isolates as *Candida dubliniensis*. Mycoses. 1999;42(1-2):29-32.
6. Moran GP, Sullivan DJ, Henman MC, McCreary CE, Harrington BJ, Shanley DB, et al. Antifungal drug susceptibilities of oral *Candida dubliniensis* isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother. 1997;41(3):617-23.
7. Alex D, Gay-Andrieu F, May J, Thampi L, Dou DF, Mooney A, et al. Amino acid-derived 1,2-benzisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets. Antimicrob Agents Ch. 2012;56(9):4630-9.
8. Branco J, Silva AP, Silva RM, Silva-Dias A, Pina-Vaz C, Butler G, et al. Fluconazole and voriconazole resistance in *Candida parapsilosis* is conferred by gain-of-function mutations in *MRR1* transcription factor gene. Antimicrob Agents Chemother. 2015;59(10):6629-33.
9. Gregori C, Schueller C, Roetzer A, Schwarzmuller T, Ammerer G, Kuchler K. The high-osmolarity glycerol response pathway in the human fungal pathogen *Candida glabrata* strain ATCC 2001 lacks a signaling branch that operates in baker's yeast. Eukaryotic Cell. 2007;6(9):1635-45.
10. Pathirana RU, Friedman J, Norris HL, Salvatori O, McCall AD, Kay J, et al. Fluconazole-resistant *Candida auris* Is susceptible to salivary histatin 5 killing and to intrinsic host defenses. Antimicrob Agents Ch. 2018;62(2).
11. Rex JH, Cooper CR, Jr., Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant *Candida* isolates in a broth-based system. Antimicrob Agents Chemother. 1995;39(4):906-9.
12. Min K, Ichikawa Y, Woolford CA, Mitchell AP. *Candida albicans* Gene Deletion with a Transient CRISPR-Cas9 System. mSphere. 2016;1(3).
13. Basso LR, Jr., Bartiss A, Mao Y, Gast CE, Coelho PS, Snyder M, et al. Transformation of *Candida albicans* with a synthetic hygromycin B resistance gene. Yeast. 2010;27(12):1039-48.
14. Wilson RB, Davis D, Mitchell AP. Rapid hypothesis testing with *Candida albicans* through gene disruption with short homology regions. J Bacteriol. 1999;181(6):1868-74.
15. Shanks RM, Caiazza NC, Hinsa SM, Toutain CM, O'Toole GA. *Saccharomyces cerevisiae*-based molecular tool kit for manipulation of genes from gram-negative bacteria. Appl Environ Microbiol. 2006;72(7):5027-36.

*Available at https://phaffcollection.ucdavis.edu